408 related articles for article (PubMed ID: 15793112)
21. Efficacy and safety of extemporaneously prepared miconazole eye drops in Candida albicans-induced keratomycosis.
Gyanfosu L; Koffuor GA; Kyei S; Ababio-Danso B; Peprah-Donkor K; Nyansah WB; Asare F
Int Ophthalmol; 2018 Oct; 38(5):2089-2100. PubMed ID: 28900810
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of antifungal agents in the cornea. II. Influence of corticosteroids.
O'Day DM; Ray WA; Robinson R; Head WS
Invest Ophthalmol Vis Sci; 1984 Mar; 25(3):331-5. PubMed ID: 6321389
[TBL] [Abstract][Full Text] [Related]
23. Successful topical application of a new antifungal agent, micafungin, in the treatment of refractory fungal corneal ulcers: report of three cases and literature review.
Matsumoto Y; Dogru M; Goto E; Fujishima H; Tsubota K
Cornea; 2005 Aug; 24(6):748-53. PubMed ID: 16015098
[TBL] [Abstract][Full Text] [Related]
24. Fungal Keratitis Caused by
Kim TH; Jun I; Lee HK; Seo KY; Kim TI; Kim EK
Korean J Ophthalmol; 2020 Aug; 34(4):336-337. PubMed ID: 32783428
[No Abstract] [Full Text] [Related]
25. Candida interface keratitis after deep anterior lamellar keratoplasty: clinical, microbiologic, histopathologic, and confocal microscopic reports.
Kanavi MR; Foroutan AR; Kamel MR; Afsar N; Javadi MA
Cornea; 2007 Sep; 26(8):913-6. PubMed ID: 17721287
[TBL] [Abstract][Full Text] [Related]
26. The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis.
Matsumoto Y; Murat D; Kojima T; Shimazaki J; Tsubota K
Br J Ophthalmol; 2011 Oct; 95(10):1406-9. PubMed ID: 21097785
[TBL] [Abstract][Full Text] [Related]
27. Assessment safety and efficacy of a combination therapy of topical amphotericin B and subconjunctival fluconazole for the treatment of fungal keratitis.
Mahdy RA; Nada WM; Wageh MM; Kader MA; Saleh MM; Alswad MM
Cutan Ocul Toxicol; 2010 Sep; 29(3):193-7. PubMed ID: 20462395
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of caspofungin eye drops in fungal keratitis.
Neoh CF; Daniell M; Chen SC; Stewart K; Kong DC
Int J Antimicrob Agents; 2014 Aug; 44(2):96-104. PubMed ID: 24933448
[TBL] [Abstract][Full Text] [Related]
29. Comparison of corneal collagen cross-linking (PACK-CXL) and voriconazole treatments in experimental fungal keratitis.
Özdemir HB; Kalkancı A; Bilgihan K; Göçün PU; Öğüt B; Karakurt F; Erdoğan M
Acta Ophthalmol; 2019 Feb; 97(1):e91-e96. PubMed ID: 29862655
[TBL] [Abstract][Full Text] [Related]
30. Antimycotic Efficacy and Safety of a New Cold Corneal Storage Medium by Time-Kill and Toxicity Studies.
Giurgola L; Gatto C; Parel JM; Miller D; DʼAmato Tóthová J
Cornea; 2019 Oct; 38(10):1314-1321. PubMed ID: 31335527
[TBL] [Abstract][Full Text] [Related]
31. Comparative antifungal susceptibility analysis of Candida albicans versus non-albicans Candida corneal isolates.
Spierer O; Dugar J; Miller D; OʼBrien TP
Cornea; 2015 May; 34(5):576-9. PubMed ID: 25826327
[TBL] [Abstract][Full Text] [Related]
32. Antifungal activity against planktonic and biofilm Candida albicans in an experimental model of foreign-body infection.
Maiolo EM; Oliva A; Furustrand Tafin U; Perrotet N; Borens O; Trampuz A
J Infect; 2016 Mar; 72(3):386-92. PubMed ID: 26723911
[TBL] [Abstract][Full Text] [Related]
33. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
34. Natamycin treatment of experimental Candida albicans induced keratomycosis in rabbits.
Saleem M; Rahman A; Afza N
West Indian Med J; 2007 Dec; 56(6):526-9. PubMed ID: 18646497
[TBL] [Abstract][Full Text] [Related]
35. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
Louie A; Deziel M; Liu W; Drusano MF; Gumbo T; Drusano GL
Antimicrob Agents Chemother; 2005 Dec; 49(12):5058-68. PubMed ID: 16304173
[TBL] [Abstract][Full Text] [Related]
37. Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient--case report and review of literature.
Bacak V; Biocina B; Starcevic B; Gertler S; Begovac J
J Infect; 2006 Jul; 53(1):e11-4. PubMed ID: 16274746
[TBL] [Abstract][Full Text] [Related]
38. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
39. Caspofungin versus amphotericin B for the treatment of Candidal esophagitis.
Chocarro Martínez A; Gonzalez A; Garcia I
Clin Infect Dis; 2002 Jul; 35(1):107; author reply 107-8. PubMed ID: 12060888
[No Abstract] [Full Text] [Related]
40. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model.
Shuford JA; Rouse MS; Piper KE; Steckelberg JM; Patel R
J Infect Dis; 2006 Sep; 194(5):710-3. PubMed ID: 16897672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
